Glioblastoma extent of resection and survival
In glioblastoma (GBM), how much enhancing tumor can be removed safely remains one of the most practical decisions in the operating room. Contemporary evidence continues to link smaller postoperative residual volume with better survival endpoints, while underscoring that “maximal” resection only helps when neurologic function is protected.
What changed / Why it matters
Decades of observational cohorts and meta-analyses have associated greater extent of resection (EOR) of contrast-enhancing disease with longer overall survival and progression-free survival in newly diagnosed GBM, after adjusting for age, performance status, and MGMT context where available. More recent volumetric work has shifted emphasis from percentage EOR alone toward absolute residual enhancing volume: patients left with very small residuals (commonly discussed thresholds in the low single-digit cubic centimeters, and in some series nearer to ≤1–5 cm³ depending on cohort and modeling) tend to show more favorable survival curves than those with larger leftovers—even when percentage resection looks similar. Residual volume is a concrete, measurable target that maps directly to postoperative MRI review and adjuvant planning.
5-ALA (fluorescence-guided) surgery improved rates of complete resection of enhancing tumor in landmark randomized and subsequent real-world series by highlighting tumor tissue that is easy to leave at the margin under white light alone. Fluorescence is an adjunct, not a license for indiscriminate removal: non-enhancing infiltrative disease, eloquence, and false-positive fluorescence still require anatomic judgment, neuronavigation, and, when indicated, mapping or monitoring. Technology expands the safe window; it does not redefine eloquence.
For practice, the actionable frame is maximal safe cytoreduction: pursue the smallest residual enhancing volume compatible with the patient’s preoperative deficits, lesion topography, and acceptable risk to motor, language, visual, and cognitive networks. In non-eloquent territory, carefully selected cases may allow more generous resection of FLAIR-abnormal tissue beyond the enhancing core; in eloquent or deep locations, stopping at a function-preserving margin is appropriate even if residual volume is not zero. Postoperative early MRI remains essential to quantify residual disease, distinguish cavity blood products from tumor, and calibrate temozolomide/radiotherapy expectations and trial eligibility.
Patient takeaway
For someone facing GBM surgery, the goal is not “as much tissue as possible at any cost,” but the safest complete removal of enhancing tumor that modern guidance (including fluorescence where available) can support. Smaller leftover enhancing volume is generally linked with better survival statistics in published series, yet preserved speech, strength, and independence often matter as much as the Kaplan–Meier curve. Ask your surgeon how residual volume will be measured on early MRI and how eloquence will be protected.
Disclaimer
This post is general educational information for patients and referring clinicians. It is not individualized medical advice, does not replace multidisciplinary tumor-board judgment, and does not claim personal or institutional outcome statistics. GBM management must be tailored to imaging, molecular markers, comorbidity, and goals of care.
Dr. Wasif Rizwan Malik
Educational only — not a substitute for clinical consultation. This daily brief is separate from the weekly Neuro Council deep-dive. Calendar day 1 — one topic, one upload.
AI WhatsApp: 0300 087 4232 — booking & PA assistant
AI booking & PA assistant — appointments and a brief note on lab reports. Does not diagnose. Does not interpret imaging for patients. Emergencies escalate to the doctor. AI limits & privacy
Emergency — direct Dr Wasif: 0345 825 4232 (not for routine booking)